Sacral Neuromodulation for Male Overactive Bladder

This study is looking at the Axonics SNM System, a device used to treat overactive bladder (OAB) in men. OAB can cause urinary urgency incontinence (UUI), which is a strong, sudden need to urinate that's hard to hold back, or frequent urination (UF). This study is for men aged 18 or older who have OAB, especially those who have had prostate surgery for benign prostatic hyperplasia (BPH) or prostate cancer. Researchers want to see how well the Axonics SNM System works and if it causes any side effects over 6 months and 1 year. The study plans to enroll 150 participants, but its current status is unclear.

Study design
This is an interventional study that plans to enroll 150 male participants. It is designed to assess the outcomes of the Axonics SNM System.
What's involved
You would need to be able to complete bladder diaries and patient questionnaires, and attend all specified evaluations.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events and effectiveness for 6 months and 1 year after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06511141

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Recruiting
NAAges 18+InterventionalTreatment
Axonics, Inc.
~150 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:Axonics SNM System

At a glance

Recruiting sites
20 of 22 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse event reporting (Safety)
Measured over 6 months, 1 year
+1 more outcome measured
Overactive Bladder
Urinary Urgency Incontinence
Benign Prostatic Hyperplasia
Prostate Cancer
Prostatectomy
Urinary Frequency
22 sites across 16 states
Florida3
Alabama2
California2
Louisiana2
Texas2
Arizona1
Maryland1
Michigan1
  • Gita Ghadimi, OD · STUDY_DIRECTOR · Boston Scientific Corporation

Opens a ready-to-send draft in your own email app — review before sending.

  • Adverse event reporting (Safety)6 months, 1 year

    Device related, procedure-related and all serious adverse events

  • Performance/Effectiveness - Reduction in UUI or UF episodes6 months, 1 year

    Demonstrate a ≥ 50% reduction in the number of UUI or UF episodes on a 3-day diary